PTC Therapeutics, Inc. (PTCT) continues to make significant progress in its pipeline. This is especially true when you consider that it has already been able to report positive interim results from ...

PTC518 treatment resulted in the lowering of mutant huntingtin protein in the blood and cerebrospinal fluid. Furthermore, after 12 months of treatment, PTC518 remains safe and well tolerated. Ready to ...

- Favorable dose-dependent trends across clinical scales in Stage 2 patients at Month 12 - - Signals of dose-dependent clinical benefit relative to matched natural history cohort as well as ...

SOUTH PLAINFIELD, N.J., March 30, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of the PIVOT-HD Phase 2 clinical trial evaluating PTC518 in people with ...

PTC Therapeutics Inc. CEO Matthew Klein said the firm “achieved all we set out to [achieve] in phase II” with PTC-518 in Huntington’s disease (HD), but it wasn’t enough to excite Wall Street, as some ...

Novartis will partner with PTC Therapeutics to expand the use of PTC’s small molecule splicing platform to develop PTC’s PTC518 Huntington’s disease program and an unspecified number of related ...

SOUTH PLAINFIELD, N.J., June 21, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared interim data from the 12-week portion of the PIVOT-HD Phase 2 study of PTC518 in Huntington's ...

WARREN, N.J., May 5, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease ...